ROIV - Roivant Sciences Ltd Dividends
This article provides a detailed financial overview of Roivant Sciences Ltd (ROIV), including its market capitalization, enterprise value, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institutional ownership, and stock performance over different periods. The data indicates strong recent stock performance and significant institutional ownership.
Roivant Sciences Insider Sold Shares Worth $610,252, According to a Recent SEC Filing
This article reports on a recent SEC filing indicating that a Roivant Sciences insider sold shares worth $610,252. The transaction highlights ownership changes within the company.
ROIV - Roivant Sciences Ltd Latest SEC Filings
This article provides the latest SEC filings and a detailed financial overview for Roivant Sciences Ltd (ROIV). It includes key financial metrics such as market cap, enterprise value, income, sales, and various ratios, alongside performance indicators, institutional ownership, and insider transaction data. The stock closed at $35.13 on July 2nd, showing a slight increase.
Roivant Sciences (ROIV) director exercises options, sells 10,000 common shares
Meghan Fitzgerald, a director at Roivant Sciences (ROIV), exercised stock options to acquire 10,000 common shares at $8.80 per share and subsequently sold all 10,000 shares in an open-market transaction for an average price of $34.90 per share. Following these transactions, Fitzgerald retains 42,963 common shares and 38,578 stock options in the company. The activity was reported in a Form 4 SEC filing on July 2, 2026.
Roivant Sciences (ROIV) Left Key Russell Indexes, Is It Still 10% Below Fair Value?
Roivant Sciences (ROIV) recently exited key Russell indexes and experienced insider share sales, prompting questions about its valuation. Despite a 10.3% undervaluation based on one narrative focusing on future clinical trial success and aggressive growth, another perspective notes its high P/B ratio compared to peers. The article suggests investors review the complete data to weigh the rewards and risks, considering its mixed sentiment in the market.
Roivant Sciences (ROIV) Left Key Russell Indexes, Is It Still 10% Below Fair Value?
Roivant Sciences (ROIV) was recently removed from key Russell indexes, prompting questions about its valuation, especially given insider share sales. Despite short-term cooling, the stock has seen significant gains over the past year. While some analysts believe ROIV is undervalued by about 10% based on future growth narratives, its high P/B ratio compared to peers suggests it might already be richly priced.
Roivant Sciences(ROIV.US) Director Sells US$56.44 Million in Common Stock
A director at Roivant Sciences (ROIV.US) recently sold common stock valued at $56.44 million. This transaction indicates insider activity within the company.
Roivant Sciences (ROIV) director sells 17,750 shares after exercising options
Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options to acquire 17,750 Common Shares and subsequently sold all of them on June 29, 2026. The sales occurred in two transactions at weighted average prices of $34.71 and $34.32, totaling approximately $610,252. After these transactions, Epperly directly holds 16,474 Common Shares and 169,166 stock options.
Form 144 ROIVANT SCIENCES LTD. For: 30 June By Investing.com
This article reports on the filing of Form 144 by ROIVANT SCIENCES LTD. for June 30th. It states that the form was published on June 30, 2026, at 21:34. The article links to additional market data and news provided by Investing.com.
Roivant Sciences Director Sold Shares Worth Over $56M
Keith S. Manchester, a director and shareholder of Roivant Sciences (ROIV), sold common shares worth over $56 million in late June 2026. The sales occurred between $33.92 and $35.45 per share, with a weighted average of $34.44. Following these transactions, Manchester directly holds over 1.7 million shares and indirectly holds nearly 13.7 million shares through QVT Financial Investment Cayman Ltd.
Form 144 ROIVANT SCIENCES LTD. For: 30 June By Investing.com
This article announces the filing of Form 144 for ROIVANT SCIENCES LTD. for June 30th. It reiterates this information multiple times and includes standard market data, news headlines, and navigational content typical of a financial news platform. The core content is the Form 144 filing itself.
Roivant Sciences Insider Sold Shares Worth $34,105,000, According to a Recent SEC Filing
An insider at Roivant Sciences sold shares valued at $34,105,000, as reported in a recent SEC filing. This significant transaction provides insight into insider activity at the company. Further details of the sale are likely available in the SEC document.
Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative?
Roivant Sciences (ROIV) was removed from two Russell defensive indices in late June 2026, which may impact its perceived risk and investment narrative through passive funds. While the removal doesn't immediately change clinical catalysts, it highlights the challenge of funding R&D amidst significant share repurchase activity. Investors are encouraged to consider the tension between R&D needs and the cash burn from buybacks, alongside varying analyst forecasts for profitability and fair value.
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with 14.59% Potential Upside
Roivant Sciences Ltd. (NASDAQ: ROIV) is a biotech company with a market capitalization of $24.51 billion, focusing on autoimmune and cardiopulmonary diseases. The stock, currently at $34.07, has a strong buy rating from analysts with a target price of $39.04, indicating a potential 14.59% upside. Despite negative current financials common for clinical-stage biotechs, its robust pipeline and positive technical indicators make it an attractive, albeit speculative, investment for growth-oriented investors.
Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing
An insider at Roivant Sciences sold shares valued at $6,631,268, as disclosed in a recent SEC filing. This transaction indicates a significant insider sell-off. The exact details of the insider, the number of shares, and the specific date of the transaction would typically be found within the SEC filing itself.
Understanding the Setup: (ROIV) and Scalable Risk
This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV), identifying strong sentiment across all horizons and an exceptional 27.7:1 risk-reward short setup. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis. The piece emphasizes sophisticated risk management to optimize position sizing and minimize drawdown risk for ROIV.
Price to sales forward of Roivant Sciences Ltd. – NASDAQ:ROIV
This article briefly displays the price to sales forward data for Roivant Sciences Ltd. (NASDAQ: ROIV). It presents the stock's financial overview on the Nasdaq Stock Market, indicated by its ticker ROIV. The article is part of a larger financial data platform, TradingView, which provides various analytical tools and market data services.
Enterprise value to revenue forward of Roivant Sciences Ltd. – DUS:87S
This article focuses on the enterprise value to revenue forward for Roivant Sciences Ltd. (DUS:87S). It highlights financial data available on TradingView for the company, accessible through the Dusseldorf Stock Exchange. The content is primarily a data point page from a financial platform rather than an analytical article.
Enterprise value to EBITDA forward of Roivant Sciences Ltd. – DUS:87S
The article displays the enterprise value to EBITDA forward for Roivant Sciences Ltd. (DUS:87S). It indicates that the market was closed at the time of viewing, with no trades observed. The content is presented within the context of TradingView's financial data and tools.
Enterprise value to EBIT forward of Roivant Sciences Ltd. – NASDAQ:ROIV
The article provides financial metrics for Roivant Sciences Ltd. (NASDAQ: ROIV), specifically focusing on its enterprise value to EBIT forward ratio. The content lists the company's stock exchange information and refers to available financial data, news, and other analyses from TradingView.
Form 144 ROIVANT SCIENCES LTD. For: 26 June By Investing.com
This article announces the filing of Form 144 by Roivant Sciences Ltd. for June 26. These forms are typically filed by insiders (affiliates) of a company who intend to sell restricted or controlled securities. The filing suggests potential insider trading activity related to ROIV shares.
Roivant (NASDAQ: ROIV) president sells 200K shares, exercises 200K stock options
Roivant Sciences Ltd.'s President & Immunovant CEO, Eric Venker, recently executed insider transactions involving the exercise of 200,000 stock options at $3.85 per share and the subsequent sale of all 200,000 common shares. The sales occurred in two separate transactions at weighted average prices of $33.51 for 46,234 shares and $33.05 for 153,766 shares. Following these transactions, Venker directly holds 1,813,063 common shares and 4,244,834 stock options.
Form 144 ROIVANT SCIENCES LTD. For: 25 June By Investing.com
The article reports on a Form 144 filing by ROIVANT SCIENCES LTD. for June 25th. Form 144 is a notice of the intent to sell restricted securities. The content also includes a standard disclaimer about the high risks involved in trading financial instruments and cryptocurrencies.
Form 144 ROIVANT SCIENCES LTD. For: 25 June By Investing.com
This article announces the filing of Form 144 by Roivant Sciences Ltd. for June 25. It specifically mentions Roivant Sciences with stock symbol ROIV and notes a slight increase in its share price. The piece reiterates the form details multiple times and includes various market data and other news headlines.
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV
This article provides the "Price to book forward" financial metric for Roivant Sciences Ltd. (NASDAQ:ROIV). It also details various data sources for market and reference information used on the platform. The content is primarily a data point surrounded by the structure of a financial analysis platform.
Morgan Stanley Smith Barney files 500,000-share sale (NASDAQ: ROIV)
Morgan Stanley Smith Barney LLC Executive Financial Services has filed a Form 144 indicating an intended sale of 500,000 shares of Roivant Sciences Ltd. (NASDAQ: ROIV) common stock. This sale, valued at $17,066,500.00, is due to an "Exercise of Options Under a Registered Plan" and is routed through the issuer for cash on June 25, 2026. The filing emphasizes transparency regarding the disposition of a large block of shares which can impact the stock's price.
Roivant Sciences stock hits all-time high at 32.8 USD
Roivant Sciences (ROIV) stock reached an all-time high of $32.80, marking a 185.44% increase over the past year and a market capitalization of $23.43 billion. Despite an InvestingPro analysis suggesting it may be overvalued, the company holds more cash than debt. Recent Q4 2026 earnings showed a significant EPS beat, though revenue fell short, and analysts have raised price targets citing positive trial data for IMVT-1402 and progress in other pipeline assets.
Roivant Sciences stock hits all-time high at 32.8 USD By Investing.com
Roivant Sciences stock reached an all-time high of $32.80, marking a significant achievement with a 185.44% surge over the past year and a market capitalization of $23.43 billion. Despite an InvestingPro analysis suggesting overvaluation, the company holds more cash than debt. Recent reports show a Q4 2026 EPS of $0.28, significantly exceeding forecasts, and analysts have raised price targets based on positive trial data for IMVT-1402 and mosliciguat.
What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders
Roivant Sciences recently secured a $2.25 billion settlement with Moderna, resolving patent-infringement litigation. Concurrent with this, the company reported positive clinical results for IMVT-1402 in rheumatoid arthritis and received Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis. These developments reduce legal uncertainty, underscore Roivant's clinical progress in immunology, and are expected to positively influence its financial flexibility and future risk-reward profile, reinforcing the importance of its late-stage pipeline.
What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders
Roivant Sciences recently settled patent infringement litigation with Moderna for $2.25 billion and reported positive clinical results for IMVT-1402 and Breakthrough Therapy Designation for brepocitinib. These developments reduce legal uncertainty and highlight Roivant's progress in immunology, supporting its pipeline and potentially improving its financial flexibility. The company's future value hinges on converting its late-stage immunology programs into approved commercial products.
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) has garnered attention due to a $2.25 billion settlement with Moderna, positive IMVT-1402 rheumatoid arthritis data, and Breakthrough Therapy Designation for brepocitinib. The stock is currently trading at $31.43, which analysts estimate to be 19.5% undervalued compared to a fair value of $39.04. Despite the optimism, the article highlights significant execution risks related to its clinical calendar and competitive pressures.
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) appears to be 19.5% undervalued following a US$2.25 billion settlement with Moderna, positive rheumatoid arthritis data for IMVT-1402, and Breakthrough Therapy Designation for brepocitinib. The stock currently trades at $31.43 against an analyst consensus target and intrinsic value estimate of $39.04. While recent catalysts have generated optimism, potential risks include a crowded clinical calendar and competitive pressures, which investors should consider alongside the reported upside.
Roivant Sciences Ltd (ROIV) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Roivant Sciences Ltd (ROIV), highlighting its current risk score and market performance indicators. With a risk assessment score of 8.62, ROIV ranks 23 out of 157 in the Pharmaceuticals industry, indicating a slightly elevated risk profile. The company's beta of 1.14 suggests higher volatility compared to the S&P 500 index.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV)
This article summarizes recent analyst ratings for three healthcare stocks: enGene Holdings (ENGN), Medtronic (MDT), and Roivant Sciences (ROIV). Analysts have mixed opinions, with enGene Holdings receiving a "Hold" from Guggenheim and a "Moderate Buy" consensus, Medtronic getting a "Hold" from Piper Sandler and a "Moderate Buy" consensus, and Roivant Sciences earning a "Buy" from Piper Sandler and a "Strong Buy" consensus. The article highlights price targets and analyst success rates for each company.
Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Roivant Sciences Ltd's (ROIV) revenue breakdown for FY2025Q1. The primary business segment contributing revenue is VTAMA, generating $55.13 million. All reported revenue is attributed to the United States region.
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory
Roivant Sciences Ltd. (NASDAQ: ROIV) is highlighted as a top growth stock in oversold territory after reporting strong financial results for FY2026, including $4.3 billion in cash and a significant settlement with Moderna. The company has a robust clinical pipeline with upcoming readouts and product launches in immunology, dermatology, and rare diseases. Despite potential risks, its strategic trajectory points to continued momentum.
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40
Piper Sandler has reiterated its Buy rating on Roivant Sciences (ROIV.US) and maintained its price target of $40. This indicates a continued positive outlook on the company's stock performance and valuation by the investment bank.
12 Best Beaten Down Growth Stocks to Buy Right Now
This article identifies Roivant Sciences Ltd. (NASDAQ: ROIV) as a key "beaten down" growth stock, highlighting its strong financial position with $4.3 billion in cash and marketable securities and a significant $2.25 billion settlement with Moderna. The company also boasts a promising clinical pipeline, with positive results for IMVT-1402 in rheumatoid arthritis and Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis, positioning it for potential growth through upcoming clinical readouts and product launches in late 2026.
12 Best Beaten Down Growth Stocks to Buy Right Now
This article identifies Roivant Sciences Ltd. (NASDAQ: ROIV) as one of the best beaten-down growth stocks to buy, highlighting its strong financial position and promising clinical pipeline. Roivant recently reported positive financial results for FY2026, including a significant settlement with Moderna and positive clinical trial readouts for several drug candidates. The company maintains a strong strategic trajectory with multiple clinical readouts and commercial launches anticipated in H2 2026.
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 29.97% Upside in Biotech Innovation
Roivant Sciences Ltd. (ROIV) is analyzed as a promising biotech company with a potential 29.97% upside, driven by its innovative pipeline in autoimmune and cardiopulmonary diseases and strong analyst support. Despite financial challenges common to clinical-stage biotech firms, such as negative EPS and high R&D costs, its strategic platforms and lead programs like mosliciguat offer significant future revenue potential. Investors are advised to balance the growth opportunities against the inherent risks and volatility of the biotech sector.
Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV
Te Ahumairangi Investment Management Ltd reduced its stake in Roivant Sciences Ltd. by 33.6% in the fourth quarter of the previous year, selling 54,800 shares. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for Roivant Sciences with an average price target of $33.59. The company recently reported better-than-expected quarterly earnings per share but missed revenue estimates, while notable insider selling also occurred.
Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV
Clearbridge Investments LLC increased its stake in Roivant Sciences Ltd. by 7.7% in the fourth quarter, purchasing an additional 141,549 shares to bring its total holding to nearly 2 million shares valued at $42.8 million. Roivant Sciences has experienced significant institutional buying, with hedge funds and other investors owning approximately 64.76% of the company's stock. The company also reported a surprise quarterly profit of $0.28 per share, surpassing analyst estimates, and maintains a "Moderate Buy" consensus rating with a price target of $33.59.
Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV
Bank of New York Mellon Corp reduced its stake in Roivant Sciences Ltd. by 37.3% in the fourth quarter, yet still holds 2.9 million shares valued at approximately $63 million. Despite a recent earnings beat on EPS, revenue fell short of estimates, and the company continues to post negative profitability. Analysts largely maintain a "Moderate Buy" rating, with several firms raising price targets.
TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV
TD Asset Management Inc. significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during Q4, purchasing an additional 235,176 shares, bringing its total to 551,376 shares valued at $12.0 million. Other major institutions like Vanguard and UBS also raised their holdings, pushing institutional ownership to 64.76%. Despite recent insider selling by the CEO and a director, analysts maintain a "Moderate Buy" rating for Roivant Sciences with an average target price of $33.59.
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)
Guggenheim maintained a Buy rating on Roivant Sciences Ltd. (ROIV) and increased its price target to $36, following the company's fiscal Q4 earnings and pipeline updates. Citi also raised its price target to $42 and reiterated a Buy rating, citing potential upside from second-half 2026 data catalysts. Roivant reported $4.3 billion in consolidated cash and equivalents, with increased R&D expenses, as it continues to develop biopharmaceutical products.
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11
Roivant Sciences Ltd. presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation, featuring analyst Corinne Jenkins, focused on insights and updates regarding the company. The full transcript of the event is available to subscribers.
CenterBook Partners LP Purchases 364,390 Shares of Roivant Sciences Ltd. $ROIV
CenterBook Partners LP significantly increased its stake in Roivant Sciences Ltd. by 147.3% in the fourth quarter, buying 364,390 shares to bring its total holdings to 611,833 shares valued at approximately $13.3 million. Wall Street analysts maintain a "Moderate Buy" rating for Roivant with an average price target of $33.59, following the company beating its quarterly EPS expectations. Despite positive institutional investment and analyst sentiment, there has been notable insider selling, including transactions by the CEO totaling millions of dollars.
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages
Roivant Sciences Ltd. (NASDAQ:ROIV) has received a "Moderate Buy" consensus rating from brokerages, with an average 1-year price target of $33.59. Various firms, including Citigroup and Guggenheim, recently raised their price targets for ROIV, despite a slight downgrade from Weiss Ratings. The company's stock rose 1.6% after reporting quarterly earnings of $0.28 per share, surpassing analyst expectations, although revenue fell below estimates.
ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of Roivant Sciences Ltd (ROIV), focusing on its revenue breakdown, profitability margins, and a comparison with competitors like INSM and INCY. ROIV exhibits a strong gross margin but negative operating and net margins, alongside a negative Return on Equity. The company's market capitalization is $20.32B, and its gross margin is benchmarked against industry peers.
Did Roivant’s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy?
Roivant Sciences (ROIV) recently reported a profitable fourth quarter with net income of US$302.99 million, despite only US$2.52 million in sales, contrasting with a full-year net loss. Concurrently, the company filed a US$981.62 million shelf registration for potential share issuance, raising questions about earnings quality and future dilution. This dual development prompts a re-evaluation of Roivant's capital strategy and investment narrative as it awaits key clinical and regulatory milestones for its late-stage immunology pipeline.
